Filing Flows › Crescent Biopharma (CBIO) › Stock forecast & fair value
Crescent Biopharma (CBIO) stock forecast and price target
Crescent Biopharma (CBIO) trades at $13.54. 6 analysts' median price target is $31.50 (+133%), from $27.00 to $36.00.
Crescent Biopharma's latest quarter
Crescent Biopharma, Q1 2026: revenue $1.0M, net loss $23.3M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for CBIO stock?
The median of 6 analysts' 12-month targets is $31.50, +133% from $13.54; the range is $27.00 to $36.00. The average rating is strong buy.
Does Crescent Biopharma usually beat earnings estimates?
It beat the consensus EPS estimate in 75% of the quarters on record.
Is CBIO stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.